Kalorama 2017 IVD Market Research Bundle (The Worldwide Market for In Vitro Diagnostic Tests, NGS, Companion, US IVD)

1: Executive Summary

Introduction

Market Metrics – Utilization

Market Metrics – Aging

Market Metrics – Disease

Market Metrics – U.S. Total Health and Clinical Lab Expenditures and Payers

Market Metrics – U.S. Clinical Testing by Channel

Impacts of the Affordable Care Act

Impacts of PAMA and LDT Reform

U.S. IVD Market

Top Tier U.S. IVD Market Participants and Rankings

Conclusions

2: Introduction to U.S. Health Care

The United States and In Vitro Diagnostics

U.S. Patient Population

Healthcare System Utilization

Aging

Disease Prevalence and Incidence

Health Insurance in the United States and the Affordable Care Act

U.S. Health Expenditure

U.S. Clinical Lab Expenditure

Affordable Care Act (ACA)

Clinical Testing under Medicare – Reimbursement Cuts and Market-Based Pricing 55

Protecting Access to Medicare Act of 2014 (PAMA)

Molecular Diagnostics and Medicare Policy

Laboratory-Developed Tests (LDTs) Invigorate Market, Challenge Regulators

U.S. Healthcare Infrastructure and Testing Channels

Hospitals

Independent Labs

Physician Office Laboratories

Self-Testing

Retail Clinics

Conclusions

3: U.S. IVD Market Analysis

Clinical Chemistry

Microbiology and Virology – ID/AST and Molecular

Point-of-Care Testing

Immunoassays

Urinalysis

Molecular Diagnostics

Coagulation

Histology

Hematology

Blood Testing and Typing

Flow Cytometry

Total U.S. IVD Market

4: Top Tier U.S. IVD Market Players

Abbott Diagnostics

Core Lab

Hematology

Molecular

Blood Testing

Mass Spectrometry ID/AST

Diabetes Testing

Point-of-Care (POC) Diagnostics

Alere

Critical Care

Lipids and Cardiac Markers

Diabetes Testing

Coagulation

Toxicology / Drugs of Abuse

Infectious Diseases

Beckman Coulter (Danaher)

Immunoassays

Clinical Chemistry

Hematology

Microbiology

Urinalysis

Flow Cytometry

Molecular

Becton, Dickinson and Company (BD)

Microbiology

Mass Spectrometry

Immunoassays

Molecular

Histology/Cytology

Flow Cytometry

bioMérieux

Microbiology

Mass Spectrometry

Immunoassays

Molecular

Sequencing

Bio-Rad Laboratories

Microbiology

Hemoglobinopathy and Diabetes Testing

Immunoassays

Blood Typing and Testing

Tissue Typing

Sequencing

Cepheid

Molecular Hospital-Acquired Infection (HAI) Testing

Molecular Sexual Health and Women’s Health Testing

Molecular Critical Infectious Disease Testing

Molecular Oncology Testing

Danaher Corporation

Histology

Point-of-Care Testing

Hologic

Molecular Cytology / Histology (HPV)

Other Molecular (STIs, HIV, HCV, TB, Respiratory)

Microbiology (AccuProbe Molecular Culture ID Tests)

Blood Testing (Molecular PROCLEIX Tests)

Johnson & Johnson (Incl. Janssen Diagnostics)

Ortho-Clinical Diagnostics

Core Lab

Blood Testing and Typing

QIAGEN

Molecular Infectious Disease

Companion Diagnostics

Immunoassays

Next-Generation Sequencing

Roche Diagnostics

Professional Diagnostics

Immunoassays

Point-of-Care Diagnostics

Diabetes Care

Tissue Diagnostics

Molecular Diagnostics

Blood Testing

Sequencing

Microbiology (GeneWeave)

Siemens Healthcare Diagnostics

Clinical Chemistry

Immunoassays

Hematology

Molecular Diagnostics and Histology

Urinalysis

Coagulation

Point-of-Care Diagnostics

Sysmex Corporation

Hematology

Coagulation

Urinalysis

Thermo Fisher Scientific

Immunoassays

Drug Testing

Histology

Mass Spectrometry

Microbiology

Molecular

Sequencing

L I S T   O F   E X H I B I T S

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER TWO: INTRODUCTION

CHAPTER THREE: MARKET ANALYSIS

CHAPTER FOUR: COMPANY PROFILES